Larissa Boaron

Hospital Universitário Cajuru

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

Paulo Gustavo Kotze

Pontifícia Universidade Católica do Paraná

Mariella Bau

Hospital Universitário Cajuru

ÁS

Álvaro Steckert Filho

Universidade Federal de Santa Catarina

Diogo Araujo Ribeiro

Hospital Universitário Cajuru

Patrícia Zacharias

Pontifícia Universidade Católica do Paraná

Renato Vismara Ropelato

Hospital Universitário Cajuru

José Donizeti de Meira Júnior

Universidade de São Paulo

Ivan Folchini de Barcelos

Hospital Universitário Cajuru

Vitória Winkeler

Monik Bordin

Cooperative Institutions

Hospital Universitário Cajuru

Pontifícia Universidade Católica do Paraná

Universidade de São Paulo

Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo

Universidade Estadual Paulista (Unesp)

Pontifical Catholic University of Puerto Rico

Pontifícia Universidade Católica de São Paulo

Pontificia Universidad Católica de Chile

American Society for Gastrointestinal Endoscopy

Hospital Universitário da Universidade de São Paulo

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

SAFETY PROFILE OF ANTI-TNF THERAPY IN CROHN’S DISEASE MANAGEMENT: A BRAZILIAN SINGLE-CENTER DIRECT RETROSPECTIVE COMPARISON BETWEEN INFLIXIMAB AND ADALIMUMAB

Arquivos de Gastroenterologia (2017)

Mariella Bau Patrícia Zacharias Diogo Araujo Ribeiro Larissa Boaron Álvaro Steckert Filho

Infliximab and adalimumab are considered effective drugs in the management of Crohn's disease. However, due to significant immunossupression, they can cause important adverse events, mostly infections.The aim of this study was to quantify and describe adverse events derived from adalimumab and infliximab use in Crohn's disease patients, and to compare the safety profile between these two agents.This was an observational, single-center, longitudinal, retrospective study with Crohn's disease patients under infliximab or adalimumab therapy. Variables analyzed: demographic characteristics (including the Montreal classification), type of agent used, concomitant immunomodulators, presence and types of adverse events observed. Patients were allocated in two groups (infliximab and adalimumab) and had their adverse events accessed and subsequently compared.A total of 130 patients were included (68 in infliximab and 62 in adalimumab groups, respectively). The groups were fully homogeneous in all baseline characteristics, with a median follow-up of 47.21±36.52 months in the infliximab group and 47.79±35.09 in the adalimumab group (P=0.512). Adverse events were found in 43/68 (63.2%) and 40/62 (64.5%) in each group, respectively (P=0.879). There were no differences between the groups regarding infections (P=0.094) or treatment interruption (P=0.091). There were higher rates of infusion reactions in the infliximab group (P=0.016). Cephalea and injection site reactions were more prevalent in adalimumab patients.Adverse events were found in approximately two thirds of Crohn's disease patients under anti-TNF therapy, and there were no significant differences between infliximab or adalimumab.

Single Center

Concomitant

10.1590/s0004-2803.201700000-43

Cite

Citations (14)

Postoperative complication rates between Crohn's disease and Colorectal cancer patients after ileocolic resections: a comparative study

Journal of Coloproctology (2017)

Larissa Boaron Luiza Facchin Mariella Bau Patrícia Zacharias Diogo Araujo Ribeiro

Abstract Introduction Ileocolic resection (ICR) is the most common surgical procedure performed for Crohn's disease (CD). Similarly, right-sided Colorectal cancer (CRC) is treated by the same operation. The primary aim of this study was to analyze and compare the frequency and profile of early postoperative complications of ICR between patients with CD and CRC. Methods Retrospective and observational study with patients submitted to ICR from two Brazilian tertiary referral units in colorectal surgery. We included patients with diagnosis of CD or CRC, treated with ICR, at any stage of follow-up. Variables analyzed: age at surgery, gender, diagnosis, surgical approach (open or laparoscopy), type of anastomosis (hand-sewn/stapled; end-to-end/side-to-side), presence and type of early postoperative complications (30 days) and mortality, among others. Results 109 patients were included, 73 with CD (67%) and 36 with CRC (33%). CD patients were younger (42.44 ± 12.73 years vs. 66.14 ± 11.02 years in the CRC groups, p < 0.0001) and had more previous resections (20 ± 27.4 in CD and 0 in CCR, p = 0.001). There were no significant differences between the groups in terms of overall early postoperative complications [17/73 (23.3%) in the CD and 5/36 (13.9%) in the CRC groups (p = 0.250)]. There was no significant difference between the groups in relation to anastomotic leakage (p = 0.185), surgical site infections (p = 0.883), other complications (0.829) and deaths (p = 0.069). Conclusions There was no significant difference in early postoperative complications in patients with CD or CRC submitted to ICR.

Colorectal Surgery

10.1016/j.jcol.2017.07.004

Cite

Citations (1)

Respiratory complications in children with mucopolysaccharidosis

Residência Pediátrica (2020)

Larissa Boaron Debora Silva Rafael Zambelli Pinto Vitória Winkeler Monik Bordin

A Residência Pediátrica (RP) é uma revista eletrônica trimestral, em publicação contínua, da Sociedade Brasileira de Pediatria (SBP), disponível em português e inglês, destinada aos médicos residentes de nossa especialidade, áreas afins e aos pediatras. O conteúdo da revista pode ser acessado livremente. A missão da RP é contribuir para a formação acadêmica dos residentes e incentivá-los a uma participação ativa na produção científica sobre temas pediátricos e relacionados à adolescência.

10.25060/residpediatr-2020.v10n1-52

Cite

Citations (1)